Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.

Malnati MS, Heltai S, Cosma A, Reitmeir P, Allgayer S, Glashoff RH, Liebrich W, Vardas E, Imami N, Westrop S, Nozza S, Tambussi G, Buttò S, Fanales-Belasio E, Ensoli B, Ensoli F, Tripiciano A, Fortis C, Lusso P, Poli G, Erfle V, Holmes H.

J Immunol Methods. 2012 Jan 31;375(1-2):46-56. doi: 10.1016/j.jim.2011.09.005.

PMID:
21963950
2.

Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses.

Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, Wurcel AG, Stone DR, Kalams SA, Trocha A, Addo MM, Goulder PJ, Walker BD.

J Immunol Methods. 2003 Apr 1;275(1-2):19-29.

PMID:
12667667
3.

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.

Fomsgaard A, Karlsson I, Gram G, Schou C, Tang S, Bang P, Kromann I, Andersen P, Andreasen LV.

Vaccine. 2011 Sep 16;29(40):7067-74. doi: 10.1016/j.vaccine.2011.07.025.

PMID:
21767590
4.

Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.

Almeida RR, Rosa DS, Ribeiro SP, Santana VC, Kallás EG, Sidney J, Sette A, Kalil J, Cunha-Neto E.

PLoS One. 2012;7(9):e45267. doi: 10.1371/journal.pone.0045267.

5.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
6.

High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level.

Yu XG, Lichterfeld M, Perkins B, Kalife E, Mui S, Chen J, Cheng M, Kang W, Alter G, Brander C, Walker BD, Altfeld M.

AIDS. 2005 Sep 23;19(14):1449-56.

PMID:
16135897
7.

MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.

Kutscher S, Allgayer S, Dembek CJ, Bogner JR, Protzer U, Goebel FD, Erfle V, Cosma A.

Gene Ther. 2010 Nov;17(11):1372-83. doi: 10.1038/gt.2010.90.

PMID:
20535218
8.

Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.

Lind A, Sommerfelt M, Holmberg JO, Baksaas I, Sørensen B, Kvale D.

Scand J Infect Dis. 2012 Aug;44(8):566-72. doi: 10.3109/00365548.2011.653581.

PMID:
22339485
9.

Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.

Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, Mahajan BA, Paranjape RS.

J Infect Dis. 2005 Sep 1;192(5):749-59.

PMID:
16088824
10.

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

Gahéry-Ségard H, Pialoux G, Figueiredo S, Igéa C, Surenaud M, Gaston J, Gras-Masse H, Lévy JP, Guillet JG.

J Virol. 2003 Oct;77(20):11220-31.

11.

Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.

De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco J, Mayer KH, Carpenter CC, Martin W.

Methods. 2004 Dec;34(4):476-87.

PMID:
15542374
12.

HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides.

Rutebemberwa A, Currier JR, Jagodzinski L, McCutchan F, Birx D, Marovich M, Cox JH.

AIDS. 2005 Jul 22;19(11):1165-72.

PMID:
15990569
14.

Immune hierarchy among HIV-1 CD8+ T cell epitopes delivered by dendritic cells depends on MHC-I binding irrespective of mode of loading and immunization in HLA-A*0201 mice.

Kloverpris HN, Karlsson I, Thorn M, Buus S, Fomsgaard A.

APMIS. 2009 Nov;117(11):849-55. doi: 10.1111/j.1600-0463.2009.02544.x.

15.

Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults.

Ratto-Kim S, Loomis-Price LD, Aronson N, Grimes J, Hill C, Williams C, El Habib R, Birx DL, Kim JH.

J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):9-17.

PMID:
12514409
17.

T cell immune responses to HIV-1.

Vasan S, Schlesinger SJ, Arrode G.

Front Biosci. 2007 Jan 1;12:2330-43. Review.

PMID:
17127243
18.

Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity.

Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ.

J Infect Dis. 2003 Jan 15;187(2):226-42.

PMID:
12552447
19.

CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.

Bansal A, Gough E, Sabbaj S, Ritter D, Yusim K, Sfakianos G, Aldrovandi G, Kaslow RA, Wilson CM, Mulligan MJ, Kilby JM, Goepfert PA.

AIDS. 2005 Feb 18;19(3):241-50.

PMID:
15718834
20.

CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotype.

Gillespie GM, Pinheiro S, Sayeid-Al-Jamee M, Alabi A, Kaye S, Sabally S, Sarge-Njie R, Njai H, Joof K, Jaye A, Whittle H, Rowland-Jones S, Dorrell L.

Eur J Immunol. 2005 May;35(5):1445-53.

Supplemental Content

Support Center